Dr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
